# Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT02101944** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Anemia
- Recurrent Multiple Myeloma
- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pelareorep

## Key facts

- **NCT ID:** NCT02101944
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-09
- **Primary completion:** 2021-05-05
- **Final completion:** 2024-05-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02101944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02101944, "Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02101944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*